These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 38767824)

  • 41. PARP inhibitors for prostate cancer.
    Longoria O; Beije N; de Bono JS
    Semin Oncol; 2024; 51(1-2):25-35. PubMed ID: 37783649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate cancer and PARP inhibitors: progress and challenges.
    Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
    J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    Cimadamore A; Cheng L; Massari F; Santoni M; Pepi L; Franzese C; Scarpelli M; Lopez-Beltran A; Galosi AB; Montironi R
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.
    Markowski MC; Sternberg CN; Wang H; Wang T; Linville L; Marshall CH; Sullivan R; King S; Lotan TL; Antonarakis ES
    Oncologist; 2024 Sep; 29(9):794-800. PubMed ID: 38885246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer.
    Agarwal N; Zhang T; Efstathiou E; Sayegh N; Engelsberg A; Saad F; Fizazi K
    Eur J Cancer; 2023 Oct; 192():113249. PubMed ID: 37672815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.
    Kostos L; Tran B; Azad AA
    Drugs; 2024 Sep; 84(9):1093-1109. PubMed ID: 39060912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Somatic or Germline Homologous Recombination Repair Gene Mutations: Phase II Single-Arm Trial.
    Jain R; Kumar A; Sharma A; Sahoo RK; Sharma A; Seth A; Nayak B; Shamim SA; Kaushal S; Kp H; Das CJ; Batra A
    JMIR Res Protoc; 2024 Apr; 13():e54086. PubMed ID: 38453159
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
    Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
    Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
    Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer.
    Brown LC; Zhu J; Mauer E; Thiede SN; Macera L; Stein MM; Taxter T; Raghavan D; Burgess EF
    JCO Precis Oncol; 2023 Sep; 7():e2300378. PubMed ID: 38061006
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multi-Gene Next-Generation Sequencing Panel for Analysis of
    Maloberti T; De Leo A; Coluccelli S; Sanza V; Gruppioni E; Altimari A; Zagnoni S; Giunchi F; Vasuri F; Fiorentino M; Mollica V; Ferrari S; Miccoli S; Visani M; Turchetti D; Massari F; Tallini G; de Biase D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    Leith A; Ribbands A; Kim J; Last M; Barlow S; Yang L; Ghate SR
    Future Oncol; 2022 Mar; 18(8):937-951. PubMed ID: 35043687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
    Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.
    Shore N; Oliver L; Shui I; Gayle A; Wong OY; Kim J; Payne S; Amin S; Ghate S
    J Urol; 2021 Apr; 205(4):977-986. PubMed ID: 33332152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.
    Kim Y; Park I; Kim B; Choi YJ; Oh SC; Lee KA
    Ann Lab Med; 2023 Jan; 43(1):64-72. PubMed ID: 36045058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Homologous recombination repair gene mutations in Malaysian prostate cancer patients.
    Saeidi H; Raju CS; Ismail P; Raub SHA; Omar N; Hisyam Bakrin I
    Cell Mol Biol (Noisy-le-grand); 2022 Aug; 68(8):22-26. PubMed ID: 36800845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
    Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
    Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.